急诊科中的并发心脑梗死:印度南部一家三级医疗中心的病例系列
本研究为印度南部一家三级医疗中心为期2年的回顾性观察研究,纳入11例成人CCI患者(AIS与AMI在24小时内发生)。多数患者就诊时已超出治疗时间窗(胸痛>12小时者73%,神经症状>4.5小时者91%),前循环卒中占91%,中位NIHSS 11分。再灌注治疗方面,18%仅接受静脉溶栓,18%接受静脉溶栓联合PCI,64%仅接受药物治疗。院内死亡率为73%。描述性比较显示幸存者入院时NIHSS评分更低、ASPECTS和GCS评分更高。
要点
- CCI患者就诊常已超时间窗:胸痛>12小时者占73%,神经症状>4.5小时者占91%,导致再灌注治疗资格有限。
- 11例患者中仅3例同时符合AIS和AMI治疗窗,3例仅符合AMI治疗,1例仅符合AIS治疗,4例两者均超窗。
- 再灌注实施:18%仅静脉溶栓,18%静脉溶栓联合PCI,64%仅药物治疗。
- 院内死亡率73%;幸存者入院时NIHSS更低、ASPECTS和GCS更高。
- 急诊需早期识别、快速风险分层和多学科协作决策以优化这类双重血管急症结局。
适用人群与场景
- 成人患者,AIS与AMI在24小时内发生(CCI定义),就诊于三级医疗中心急诊科。
- 研究期间为2年,来自印度南部单中心。
诊断标准与关键阈值
- CCI定义为急性缺血性卒中(AIS)与急性心肌梗死(AMI)近乎同时发生,本研究纳入两者在24小时内发生的患者。
- 治疗时间窗:胸痛>12小时视为超出AMI治疗窗;神经症状>4.5小时视为超出AIS治疗窗。
- 神经功能评估:NIHSS中位11分(IQR 7-18),前循环卒中占91%。
处置流程与药物剂量
- 再灌注策略需根据AIS和AMI各自时间窗及 eligibility 决定:3例同时符合两者治疗窗,3例仅符合AMI,1例仅符合AIS,4例均超窗。
- 实际治疗:18%仅静脉溶栓,18%静脉溶栓联合PCI,64%仅药物治疗。
- 原文未提及具体药物剂量、给药途径、频次或目标值。
红旗征与不能漏的情况
- 就诊延迟:胸痛>12小时(73%)或神经症状>4.5小时(91%)提示错过再灌注时间窗,需快速评估但仍应启动相应流程。
- 严重神经功能缺损(中位NIHSS 11分)与不良预后相关,幸存者NIHSS更低。
- CCI为危及生命的双重血管急症,管理优先事项复杂且常冲突,需多学科协作。
研究设计与关键结果
- 研究类型:单中心回顾性观察研究,样本量11例,来自印度南部三级医疗中心,为期2年。
- 人群:成人CCI患者,AIS与AMI在24小时内发生;中位年龄55岁(IQR 38-65),男性73%。
- 主要终点:院内死亡率73%。
- 治疗资格:3例同时符合AIS和AMI治疗窗,3例仅符合AMI,1例仅符合AIS,4例均超窗。
- 再灌注:18%仅静脉溶栓,18%静脉溶栓联合PCI,64%仅药物治疗。
- 描述性比较:幸存者入院时NIHSS更低、ASPECTS和GCS更高。
证据类型、等级与局限
- 证据类型:回顾性观察性病例系列(单中心,样本量11例),无对照组,仅描述性比较。
- 局限:样本量小、单中心、回顾性设计、无统计推断或效应量估计,结果需前瞻性验证。
对床旁实践的改变
- 急诊面对CCI患者应早期识别双重血管急症,快速评估AIS和AMI各自时间窗及再灌注资格。
- 就诊延迟常见,需迅速风险分层并协调神经科与心内科等多学科决策,避免因管理冲突延误治疗。
- 严重神经功能缺损(高NIHSS、低ASPECTS/GCS)提示预后差,应与家属沟通不良预后可能。
- 本研究样本小且为回顾性,不能据此改变具体再灌注方案选择,需个体化决策。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Concurrent cardiocerebral infarction (CCI), defined as the near-simultaneous occurrence of acute ischemic stroke (AIS) and acute myocardial infarction (AMI), is a rare but life-threatening emergency with complex and often conflicting management priorities. Evidence guiding optimal treatment strategies remains limited.
METHODS: We conducted a retrospective observational study of adult patients presenting with CCI to the emergency department of a tertiary care centre in South India over a 2-year period. Patients with AIS and AMI occurring within 24 h were included. Demographic, clinical, imaging, treatment, and outcome data were extracted. Descriptive comparisons were performed to summarize differences between survivors and non-survivors. The primary outcome was in-hospital mortality.
RESULTS: A total of 11 patients were included. The median age was 55 years (IQR, 38-65), with a male predominance (73%). Most patients presented beyond established therapeutic windows (chest pain >12 h: 73%; neurological symptoms >4.5 h: 91%). Anterior circulation strokes predominated (91%), with moderate-to-severe neurological deficits (median NIHSS 11; IQR, 7-18). Regarding treatment eligibility, three patients were within the treatment window for both AIS and AMI, three were eligible for AMI treatment only, one for AIS treatment only, and four were outside the treatment window for both conditions. Reperfusion therapy consisted of intravenous thrombolysis alone in 18% and combined intravenous thrombolysis with percutaneous coronary intervention (PCI) in 18%, while 64% received medical management alone. In-hospital mortality was 73%. Descriptive comparisons showed that survivors had lower NIHSS scores and higher ASPECTS and GCS scores at presentation.
CONCLUSION: CCI is associated with high in-hospital mortality. These findings suggest that delayed presentation and limited eligibility for timely reperfusion may contribute to poor outcomes, particularly in patients with severe neurological involvement. In emergency settings, early recognition, rapid risk stratification, and coordinated multidisciplinary decision-making are critical for optimizing outcomes in this complex dual vascular emergency.
参考来源
- Jayajothi T, Amrithanand VT, Anukarthika S, et al. Concurrent cardiocerebral infarction in the emergency department: A case series from a tertiary care centre in South India. Am J Emerg Med. 2026. PMID: 42561722. doi:10.1016/j.ajem.2026.07.052
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。